Ligand-Mediated Regulation of Peroxisome Proliferator-Activated Receptor (PPAR) β/δ: A Comparative Analysis of PPAR-Selective Agonists and All-trans Retinoic Acid

被引:54
|
作者
Rieck, Markus [1 ]
Meissner, Wolfgang [1 ]
Ries, Simone [1 ]
Mueller-Bruesselbach, Sabine [1 ]
Mueller, Rolf [1 ]
机构
[1] Univ Marburg, Inst Mol Biol & Tumorforsch, D-35032 Marburg, Germany
关键词
D O I
10.1124/mol.108.050625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily that modulate target gene expression in response to natural fatty acid ligands and synthetic agonists. It is noteworthy that all trans-retinoic acid (atRA) has recently been reported to act as a ligand for PPAR beta/delta, to activate its transcriptional activity, and, in contrast to the "classic" function of atRA, to stimulate cell proliferation (Schug et al., 2007). Here, we report that in contrast to synthetic PPAR beta/delta agonists, atRA failed to induce the transcriptional activity of PPAR beta/delta using different types of reporter gene assays. Likewise, atRA did not affect the expression of the bona fide PPAR beta/delta target genes ADRP and AN-GPTL4 but strongly increased expression of the retinoic acid target gene CYP26A under the identical experimental conditions. Consistent with these observations, atRA did not compete with established PPAR beta/delta agonists in a ligand binding assay, and atRA did not enable the interaction of PPAR beta/delta with a coactivator peptide in a time-resolved fluorescence resonance energy transfer assay in vitro. These results are in sharp contrast to the effect of established PPAR beta/delta agonists in both in vitro assays. Taken as a whole, these data strongly suggest that atRA does not function as a ligand of PPAR beta/delta in any of the experimental systems tested and that the previously reported atRA effects are more likely to reflect an uncharacterized and less direct mechanism.
引用
收藏
页码:1269 / 1277
页数:9
相关论文
共 50 条
  • [21] Conjugated linoleic acid is an activator and ligand for peroxisome proliferator-activated receptor-gamma (PPARγ)
    Belury, MA
    Moya-Camarena, SY
    Lu, M
    Shi, LL
    Leesnitzer, LM
    Blanchard, SG
    NUTRITION RESEARCH, 2002, 22 (07) : 817 - 824
  • [22] The insulin receptor:: a new anticancer target for peroxisome proliferator-activated receptor-γ (PPARγ) and thiazolidinedione-PPARγ agonists
    Costa, V.
    Foti, D.
    Paonessa, F.
    Chietari, E.
    Palaia, L.
    Brunetti, G.
    Gulletta, E.
    Fusco, A.
    Brunetti, A.
    ENDOCRINE-RELATED CANCER, 2008, 15 (01) : 325 - 335
  • [23] Heterodimer formation with retinoic acid receptor RXRα modulates coactivator recruitment by peroxisome proliferator-activated receptor PPARγ
    Kilu, Whitney
    Merk, Daniel
    Steinhilber, Dieter
    Proschak, Ewgenij
    Heering, Jan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 297 (01)
  • [24] Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR-γ): a review
    Wang, Limei
    Waltenberger, Birgit
    Pferschy-Wenzig, Eva-Maria
    Blunder, Martina
    Liu, Xin
    Malainer, Clemens
    Blazevic, Tina
    Schwaiger, Stefan
    Rollinger, Judith M.
    Heiss, Elke H.
    Schuster, Daniela
    Kopp, Brigitte
    Bauer, Rudolf
    Stuppner, Hermann
    Dirsch, Verena M.
    Atanasov, Atanas G.
    BIOCHEMICAL PHARMACOLOGY, 2014, 92 (01) : 73 - 89
  • [25] Benzimidazolones: A New Class of Selective Peroxisome Proliferator-Activated Receptor γ (PPARγ) Modulators
    Liu, Weiguo
    Lau, Fiona
    Liu, Kun
    Wood, Harold B.
    Zhou, Gaochao
    Chen, Yuli
    Li, Ying
    Akiyama, Taro E.
    Castriota, Gino
    Einstein, Monica
    Wang, Chualin
    McCann, Margaret E.
    Doebber, Thomas W.
    Wu, Margaret
    Chang, Ching H.
    McNamara, Lesley
    McKeever, Brian
    Mosley, Ralph T.
    Berger, Joel P.
    Meinke, Peter T.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (24) : 8541 - 8554
  • [26] Peroxisome proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders
    Seminotti, Bianca
    Grings, Mateus
    Vockley, Jerry
    Leipnitz, Guilhian
    BIOCHEMICAL PHARMACOLOGY, 2023, 209
  • [27] Role of peroxisome proliferator-activated receptor (PPAR) agonists in experimental liver fibrosis in rats
    Ghoneim, MT
    El-Azim, TA
    Baraka, AM
    Matta, MM
    El-Din, NMN
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R89 - R89
  • [28] Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPARα)-activation by phenylpropanoic acid-type PPARα agonists
    Miyachi, H
    Uchiki, H
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (19) : 3145 - 3149
  • [29] Peroxisome proliferator-activated receptor (PPAR) α and γ agonists directly bind and close KATP channel
    Shimomura, K
    Shimizu, H
    Ikeda, M
    Matsumoto, S
    Mori, M
    DIABETES, 2003, 52 : A369 - A369
  • [30] In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database
    Feng, Xiao-Yan
    Ding, Ting-Ting
    Liu, Ya-Ya
    Xu, Wei-Ren
    Cheng, Xian-Chao
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (05): : 1853 - 1864